AFFINITY IMAGE-INSTRUMENTATION FOR DRUG DISCOVERY

通过筛选组合文库来发现药物先导已经成为许多制药公司的一项重要任务，由于产生了大量的化合物，因此有必要使用池中的方法而不是单独的方法来测试文库。智能光学系统，提出了一种快速、廉价的小型化、自动化。用于高通量(HTS)和超高通量(UHTS)筛选分析中组合文库的快速筛选和表征的高灵敏度、无标记的光学成像仪(“亲和图像”)。拟议的仪器将非常灵活，有可能同时对4000多个不同的目标进行动态和平衡分析。由于不需要标签，而且可以同时进行多种检测，该仪器为该行业节省了大量的材料和人力成本。亲和图像作为HTS应用工具的可行性将通过模型系统进行演示。在该项目的第一阶段，将测试两个模型系统：(L)抗b-内啡肽抗体的表位映射和(2)与链霉亲和素生物素结合位点结合的探测肽和非肽配体。拟议的商业应用：亲和图像将是参与药物发现的制药和生物技术行业的主要兴趣所在。Affacy Image将出售给世界各地拥有多个研究地点的275多家制药公司，以及几乎所有其他私人、学术和公共支持的生物分析实验室。

The discovery of drug leads by screening combinatorial libraries has become an important mandate of many pharmaceutical companies.Because of the vast number of compounds produced it is necessary to employ methods for testing the libraries in pools rather than individually. Intelligent Optical Systems, proposes a fast, inexpensive miniaturized, automated. highly sensitive, labelless, optical imaging instrument ("Affinity Image") for rapid screening and characterization of combinatorial libraries in high-throughput (HTS) and ultra high- throughput (UHTS) screening assays. The proposed instrument will be extremely flexible and will have the potential to perform dynamic and equilibrium assays for more than 4000 different targets simultaneously. Since no labels are needed and multiple assays can be performed simultaneously this instrument represents substantial savings in the material and labor costs for the industry. The feasibility of Affinity Image as a tool for HTS applications will be demonstrated with model systems. During Phase I of this project two model systems will be tested: (l) epitope mapping of anti-b-endorphin antibody and (2) probing peptide and nonpeptide ligands that bind to the biotin binding site of streptavidin. PROPOSED COMMERCIAL APPLICATIONS: Affinity Image will be of primary interest to pharmaceutical and biotechnology industries involved in drug discovery. Affinity Image would be sold to more than 275 pharmaceutical companies worldwide with multiple research locations and to virtually all other private, academic, and publically supported bioanalytical laboratories.